6th June 2013

Mirada Medical PET/MRI software highlighted in multiple research studies presented at SNMMI annual meeting

Denver, CO, June 06, 2013: Mirada Medical collaborators will be presenting novel PET/MRI research at the annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting being held June 8-12 in Vancouver, British Columbia. Mirada will showcase how its software tools support clinicians and researchers to unlock the potential of PET/MRI and Molecular Imaging in a talk being presented by Dr. Timor Kadir PhD, Mirada Chief Science and Technology Officer, at the SNMMI Booth #1526 at 12pm on Tuesday June 11th. “PET/MRI is a rapidly developing field and Mirada is committed to providing the software tools to support the research and trials necessary to realize the potential of this critically important new modality in Molecular Imaging”, says Dr. Timor Kadir. “Our software supports both the hardware hybrid scanners and provides state-of-the-art validated deformable registration for software based PET/CT/MRI.” Evidence of this is the host of validated research studies being presented at this year’s SNMMI meeting by renowned scientists from prestigious institutions around the globe, a growing number of whom utilize Mirada software products for image and data review and analysis. Prof. David Townsend, Director of the A*STAR-NUS Clinical Imaging Research Centre (CIRC) in Singapore, will present a paper entitled “Initial results of the assessment of PET/MR compared to PET/CT for diagnosis and staging of malignant disease” (#231) by Dr. Yan et al. of CIRC and National University Hospital, Singapore. This work is a comparative analysis of the image quality and quantification accuracy of hardware PET/MRI and PET/CT, a highly relevant topic of current interest in the field. Advanced quantification features and accurate deformable registration in Mirada PET/MRI software allowed the quantification of regions-of-interest simultaneously in both the PET/MRI and PET/CT of the same patient. Another quantification analysis is presented in the work of Dr.Thomas Klausen et al. of Rigshospitalet, Denmark, entitled “Image distortions and bias from dental restorations in PET/CT- and PET/MR-imaging” (#1409). In this work, Mirada’s support for multiple studies and multiple sequences enabled the analysis of artifacts arising from dental fillings on image quality and quantification on hardware PET/MRI and PET/CT. Mirada’s software PET/MRI is an alternative to hybrid scanners and is based on deformable registration between the PET-CT and MRI to perform the fusion. A high quality registration is critical for effective fusion between PET/CT and MRI. Mirada’s deformable registration algorithm, is the subject of another paper by Dr. Martin Lodge et al. of Johns Hopkins University entitled “Combined PET/CT/MRI of the pelvis using software registration” (#2089). This work investigates the accuracy of the deformable registration between the CT and MR in the pelvis. Mirada will be demonstrating their latest range of software tools for PET/MRI, PET/CT, Tumor Board and Amyloid image reading in their technical exhibit (Booth #320). For more information, please contact: Mirada Medical US/Worldwide: Robert Ripley                                                                       tel: (440) 591-8638 Insource Communications rripley@insourceinc.com enquiries@mirada-medical.com www.mirada-medical.com   U.S. Headquarters: Mirada Medical USA, Inc. 999 18th Street Suite 2025N Denver, CO 80202 Tel: (303) 379-9228   World Headquarters: Oxford Centre for Innovation New Road, Oxford OX1 1BY United Kingdom Tel: +44(0)1865 261410   About Mirada Medical Ltd   Mirada Medical is a leading international brand in medical imaging. The company develops advanced software applications which help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada’s products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumor board and elsewhere.   The company specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention. Mirada’s advanced software products are available throughout the world under its own brand, and on an OEM basis through a select number of the world’s leading healthcare companies.   Mirada Medical was originally spun out of the University of Oxford. The company’s technologies and products continue to be developed by their team of specialists, engineers and world-renowned scientists at Mirada’s world headquarters in Oxford, England.   Mirada Medical, RTx, Casemeeting, Caseaccess and XD3 are all trademarks of Mirada Medical Ltd.   ####   To Unsubscribe: If you want to be removed from the Mirada Medical news service, and not receive further news releases, please send a return email to the following address (rripley@insourceinc.com) with the word “Unsubscribe” on the subject line.